Literature DB >> 16580705

Genetic polymorphisms in CYP1A1 and GSTM1 predispose humans to PCBs/PCDFs-induced skin lesions.

Pei Chien Tsai1, Wenya Huang, Yeu-Chin Lee, Shih Huang Chan, Yueliang Leon Guo.   

Abstract

INTRODUCTION: Polychlorinated biphenyls (PCBs) and dibenzofurans (PCDFs) are ubiquitous persistent pollutants in humans. Whether people with different genotypes are with different susceptibility to these chemicals are unknown. In a group of people highly exposed to PCBs/PCDFs, we tested the hypothesis that genotypic polymorphisms affected susceptibility for development of skin manifestations.
METHODS: In 1979, approximately 2000 people in central Taiwan ingested cooking oil contaminated with PCBs/PCDFs. Skin disorder such as chloracne, abnormal nail, hyperkeratosis and skin allergy were found in PCBs/PCDFs exposed group. We recruited exposed and community background exposure subjects for blood testing and telephone-interview. Single nucleotide polymorphisms, AhR Arg554Lys, CYP1A1 Ile462Val, CYP1A1 T6235C, and GSTM1/T1 deletion, were determined. Occurrence of skin manifestations was compared among people with different genotypes while stratified by PCB exposure levels by logistic regression.
RESULTS: Data on exposure, medical history, and genotypes were obtained from 393 exposed and 181 background exposure groups. Skin manifestations including chloracne, allergy, abnormal nail, and hyperkeratosis were more prevalent in exposed people in a dose-related manner. Among highly exposed individuals, combined CYP1A1-MspI mutant genotype and GSTM1-null genotype were associated with increased risk of chloracne (odds ratio 2.8, 95% confidence interval 1.1-7.6). Among intermediately exposed individuals, GSTM1 null genotype was associated with skin allergy. AhR Arg554Lys genotype and GSTT1 null genotype were not related to susceptibility to skin manifestations in PCB/PCDF-exposed population.
CONCLUSION: CYP1A1 and GSTM1 genotypic polymorphisms might be related to the susceptibility to PCB/PCDF-induced skin manifestations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16580705     DOI: 10.1016/j.chemosphere.2005.08.012

Source DB:  PubMed          Journal:  Chemosphere        ISSN: 0045-6535            Impact factor:   7.086


  6 in total

1.  PCB153 reduces telomerase activity and telomere length in immortalized human skin keratinocytes (HaCaT) but not in human foreskin keratinocytes (NFK).

Authors:  P K Senthilkumar; L W Robertson; G Ludewig
Journal:  Toxicol Appl Pharmacol       Date:  2011-12-22       Impact factor: 4.219

2.  Endocrine disruption in human placenta: expression of the dioxin-inducible enzyme, CYP1A1, is correlated with that of thyroid hormone-regulated genes.

Authors:  Thomas L Wadzinski; Katherine Geromini; Judy McKinley Brewer; Ruby Bansal; Nadia Abdelouahab; Marie-France Langlois; Larissa Takser; R Thomas Zoeller
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

3.  Genetic predisposition for dermal problems in hexavalent chromium exposed population.

Authors:  Priti Sharma; Vipin Bihari; Sudhir K Agarwal; Sudhir K Goel
Journal:  J Nucleic Acids       Date:  2012-07-26

4.  Neurocognitive changes among elderly exposed to PCBs/PCDFs in Taiwan.

Authors:  Kao-Chang Lin; Nai-Wen Guo; Pei-Chien Tsai; Chiu-Yueh Yang; YueLiang Leon Guo
Journal:  Environ Health Perspect       Date:  2008-02       Impact factor: 9.031

Review 5.  Environmental toxicants and autism spectrum disorders: a systematic review.

Authors:  D A Rossignol; S J Genuis; R E Frye
Journal:  Transl Psychiatry       Date:  2014-02-11       Impact factor: 6.222

6.  Role of metabolic genes in blood arsenic concentrations of Jamaican children with and without autism spectrum disorder.

Authors:  Mohammad H Rahbar; Maureen Samms-Vaughan; Jianzhong Ma; Jan Bressler; Katherine A Loveland; Manouchehr Ardjomand-Hessabi; Aisha S Dickerson; Megan L Grove; Sydonnie Shakespeare-Pellington; Compton Beecher; Wayne McLaughlin; Eric Boerwinkle
Journal:  Int J Environ Res Public Health       Date:  2014-08-06       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.